Six Peptides DFA Names in FDA Pharmacy Access Review

Peptide Straight Talk editorial desk Flash · Sources checked October 19, 2026

❝

The peptides at issue, according to Doctors for America's October 16 statement

- BPC-157

- TB-500

- KPV

- MOTS-c

- Epitalon

- Semax

DFA says the peptides at issue "include" these six, so its list may not be complete.[5]

Do other sources match? Yes. These are the same six peptides FDA's advisory committee recommended for pharmacy compounding in July. The committee also reviewed a seventh, emideltide (DSIP), and voted against it.[4][13] Separately, AP reported, citing two unnamed sources, that BPC-157 would be included.[3]

Doctors for America's October 16 statement identifies BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax as peptides at issue in the pending policy. We have not independently confirmed which peptides the policy covers; its text is not public.

Watch the full video: Six peptides at issue in the White House review, explained

When FDA sent its "Interim Access Policy for Compounding Using Certain Peptides" to the White House on October 14, the official listing said nothing about which peptides it covered.[1] AP's sources said BPC-157 would be included.[3]

Now a fuller list is on the record. On October 16, Doctors for America (DFA), a physician group that opposes the policy, named six peptides that it said are among "the peptides at issue."[5] They line up exactly with the six an FDA advisory committee recommended in July.[4]

What's at stake is where people get these peptides. Many now buy them online from sellers labeled "research use only," with no prescription and no pharmacy oversight. AP reports that the policy would let licensed compounding pharmacies temporarily make some of them, through what's called "enforcement discretion": FDA choosing not to take certain enforcement actions under specified conditions.[3]

Who supports interim pharmacy access

Peptide-medicine physicians (AAPM). The American Academy of Peptide Medicine requested the first White House meeting on the policy.[2] Its chair, Lee Rosebush, said in a statement published October 16: "We are encouraged by this progress and see it as an important step toward safe, regulated access." Placing these peptides on the interim bulk lists, he said, "would give patients a safe, legitimate source and help eliminate the black and gray markets."[6] AAPM's public explainer puts it this way: "The answer to a risky gray market is not prohibition, which just sends more people into it."[7]

Compounding pharmacists (APC). The Alliance for Pharmacy Compounding laid out its safeguards in an August 25 letter to FDA. It asked FDA to allow compounding of the six recommended peptides through enforcement discretion, "subject to defined safeguards." Those safeguards cover sourcing and quality, prescribing, patient disclosure, serious adverse-event reporting and traceability. APC wrote that "a flourishing illicit peptide market already exists and presents a threat to public health." It argued that regulated access with guardrails protects patients better than either a blanket ban or blanket approval.[8] On the White House filing itself, APC said the policy could be significant but that its contents, covered peptides and conditions were still unknown.[9]

A committee member's conditional support. Dr. Melissa Loseke, a member of the advisory committee, called her yes vote on BPC-157 "conditional." She said she wants tighter rules on who can make the raw ingredient, mandatory side-effect reporting and patient registries.[10]

Anti-aging and peptide educators (A4M and IPS). In August, the American Academy of Anti-Aging Medicine and the International Peptide Society welcomed the advisory vote as a step toward "a regulated, evidence-informed compounding pathway." Jim LaValle, who chairs the International Peptide Society, added: "a recommendation is not an approval."[11]

Who objects, and why

Doctors for America. DFA is a nonprofit that says it mobilizes more than 40,000 physicians and medical trainees. It asked the White House budget office to send the policy back to FDA. Its central concern is identity and purity: "Pharmacy compounding can make an uncharacterized substance sterile; it cannot make it known." DFA makes two separate asks:

FDA drug approval, with clinical trials, for anyone marketing these peptides for medical use.
Notice-and-comment rulemaking (a proposed rule, public comment, then a final rule) for any addition to the 503A Bulks List.

DFA says the committee overrode FDA reviewers "on narrow 8–6 votes." That's DFA's figure. A Holland & Knight summary reports the BPC-157, KPV and TB-500 votes as 8–6 with one abstention. It reports that emideltide failed 6–7 with one abstention.[5][4]

Consumer advocates (CSPI). On October 14, the Center for Science in the Public Interest asked FDA to reject the committee's recommendations and side with its staff scientists. It also raised conflict-of-interest concerns about committee members.[12]

The safeguards both sides name

The groups disagree on the evidence, the timing and the process. Supporters want access now, with guardrails. DFA calls for drug approval and rulemaking, and CSPI wants FDA to reject the committee's recommendations. Still, some of their safeguards overlap. APC and DFA both list quality standards for the raw ingredient, mandatory reporting of serious side effects, and plain disclosure to patients that the product isn't FDA-approved. DFA lists them as conditions for any access. Dr. Loseke named ingredient controls and side-effect reporting.[5][8][10]

That overlap is what to watch. Enforceable safeguards could reduce sourcing and preparation risks if the policy opens a pharmacy route. The policy's text and how it's carried out will determine what protections patients actually get. PST's view: people are already using these peptides, so a regulated pharmacy route with real safeguards beats unverified sources.

What hasn't changed

The policy is still pending review, and its text isn't public.[1]
Neither the advisory recommendations nor the pending White House review adds these six peptides to the 503A Bulks List or makes any of them an FDA-approved drug.[4]
AP reported that HHS officials did not immediately respond to its requests for comment.[3]

What's next

OIRA's public log lists two meetings on this policy: Wednesday, October 21, at 3:00 PM ET (2:00 PM CT), requested by AAPM, and Friday, October 23, at 2:00 PM ET (1:00 PM CT), requested by Hims & Hers Health.[2] A meeting lets an outside group make its case. It isn't a decision. After review, the policy could be cleared and published, revised, returned to FDA or withdrawn. When the text comes out, we'll report exactly which peptides it covers and under what conditions.